GSK2190915

DRUG3 trials

Sponsors

GlaxoSmithKline

Conditions

Asthma

Phase 1

GSK2190915 Safety and Pharmacokinetic Study in Healthy Japanese Subjects

CompletedNCT00955383

GlaxoSmithKlineAsthma

Start: 2009-08-14End: 2009-10-12Updated: 2017-06-14

Phase 2

A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following Exercise

CompletedNCT00812929

GlaxoSmithKlineAsthma

Start: 2008-12-01End: 2009-07-15Updated: 2017-09-19

Study to Evaluate GSK2190915 in Subjects With Mild Asthma

CompletedNCT00812773

GlaxoSmithKlineAsthma

Start: 2008-12-31End: 2009-07-31Updated: 2016-10-12

Related Papers

The effect of GSK2190915, a 5-lipoxygenase‐activating protein inhibitor, on exercise-induced bronchoconstriction

Allergy and Asthma Proceedings2014-03-0111 citations